Pharma Pulse: FDA Clears First Oral Wegovy; Yusen Logistics Seals European Health Deal

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

• First, a major win for Novo Nordisk. The FDA has approved the Wegovy pill, making it the first oral GLP-1 receptor agonist cleared for weight management. In clinical trials, the once-daily pill demonstrated a 16.6% mean weight loss—comparable to the efficacy of the injectable version. This convenient, needle-free alternative is slated for a US launch in early January 2026, offering patients a flexible new option to help meet their long-term health goals.
• Turning to the supply chain, Yusen Logistics has officially completed its acquisition of Walden Group’s healthcare subsidiaries, including Movianto and Eurotranspharma. The deal establishes a dedicated European healthcare platform that connects warehousing, cold-chain transport, and digital logistics solutions. By integrating these specialized services, Yusen is strengthening its end-to-end capabilities to ensure that essential medicines and biotech products reach patients safely and reliably.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.